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Summary Exacerbation of hypoxic injury after reoxygenation is a crucial mechanism
mediating organ injury in transplantation, and in myocardial, hepatic, gastrointestinal,
cerebral, renal, and other ischemic syndromes. The occlusion and reperfusion of the splanchnic
artery is a useful animal model to elucidate the mechanism of gastrointestinal injury induced
by ischemia-reperfusion (I/R). Although xanthine oxidase is a major source of reactive oxygen
species (ROS), which plays an important role in the I/R-induced intestinal injury, there are
many other sources of intracellular ROS. Various treatment modalities have been successfully
applied to attenuate the I/R injury in animal models. This review focuses on the role of oxidant
stress in the mechanism of I/R injury and the use of antioxidant agents for its treatment.
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Introduction
Oxidant stress, such as that due to free radicals and/or
reactive oxygen species is known to cause organ injury. A
growing body of evidence indicates that oxidative stress
plays an important role in the pathogenesis of many clinical
conditions [1–3] involving cardiovascular diseases [4, 5],
liver diseases [6,  7], lung disease [8,  9], gastrointestinal
disorders [10–12], neurological disorders [13, 14], muscle
damage [15], diabetes [16], and aging [17]. The involvement
of free radicals in gastrointestinal injury observed after
ischemia-reperfusion (I/R) has also been reported [18–20].
Superoxide and hydrogen peroxide are considered to be the
major free radicals contributing to gastrointestinal injury
after I/R. Acute gastrointestinal mucosal lesions can be by
abolishing these reactive oxygen species [21].
The present review focuses on the oxidant stress during
ischemia and reperfusion injury in the gastrointestinal tract
and the use of antioxidant agents in its treatment.
Oxidant Stress during Ischemia-Reperfusion Injury
in the Gastrointestinal Tract
An important assumption that oxygen free radicals play
a crucial role in the pathogenesis of I/R has been supported
by many lines of evidence that superoxide dismutase
(SOD)—a highly specific scavenger of superoxide—prevents
I/R induced gastrointestinal injury [18, 22]. Additionally,
reperfusion-induced oxidant stress in the gastrointestinal
tract is supported by reduced glutathione (GSH) consump-
tion and concomitant formation of oxidized glutathione
(glutathione disulfide: GSSG) in the gastrointestinal mucosa
that is subjected to I/R [23, 24]. These changes are signifi-
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cantly reversed by both SOD and allopurinol. Conversely,
there are reports that the disappearance of most of the GSH
occurs during the ischemic period and GSH is not oxidized
during the I/R episode [25].
By using electron spin resonance spectrometry and low-
level chemiluminescence, Nilsson and co-workers demon-
strated that there is a burst of oxidant formation immediately
after 2–5 min of reperfusion of the ischemic intestine [26, 27].
This oxidant formation after reperfusion was supposedly
derived from the electron transport chains of the mitochondria
[28, 29], xanthine oxidase (XO) metabolism [30, 31], endo-
thelial cells [32,  33], prostaglandins [34], and activated
neutrophils [35, 36].
Since superoxide is more efficient as a reducing agent
than as an oxidizing agent, its formation is not considered
to induce high levels of cytotoxicity. Spontaneous or SOD-
catalyzed dismutation of superoxide (O2˙−) produces hydrogen
peroxide (H2O2). Additionally, superoxide—a relatively low-
energy radical—is responsible for the production of highly
reactive and harmful hydroxyl radicals (HO˙) by the Haber-
Weiss reaction.
O2˙− +H 2O2 → OH− +H O ˙+O 2
Typically, HO˙ causes biological damage by stimulating
the free chain reaction of the lipid side chains of the mem-
brane phospholipids and DNA strand breakage and causing
organelle and cell disruption [37].
Relative Contributions of Ischemia and Reperfusion
to Mucosal Injury
The interruption of blood supply results in an ischemic
injury. Paradoxically, restoration of the blood supply causes
additional cell injury that is referred to as reperfusion injury.
There are several lines of evidence in the oxygen radical
hypothesis of gastrointestinal I/R injury that tend to support
an important assumption that the tissue injury observed after
reperfusion is due to the reintroduction of oxygen rather than a
delayed manifestation of injury incurred during the ischemic
period. Parks and Granger have demonstrated that the mucosal
injury produced after 3 h ischemia followed by 1 h of re-
perfusion was significantly greater than that produced after
4 h of ischemia without reperfusion [38]. They also observed
that 3 h of intestinal ischemia followed by 1 h of reperfusion
with deoxygenated perfusate produced significantly less
mucosal injury than that produced by reperfusion with
oxygenated whole blood. Furthermore, the assumption that
reoxygenation results in greater mucosal injury after re-
perfusion is supported by the consistent observation that
antioxidants and inhibitors of oxy-radical formation (e.g.,
allopurinol) attenuate only that component of the mucosal
injury that manifests after reperfusion [39]. Ates and co-
workers demonstrated that the administration of antioxidants
immediately before reperfusion is as effective in attenuating
the mucosal injury as it would be if the antioxidant were to
be administered before ischemia [40]. Oxy-radical production
during the reperfusion period is largely responsible for the
injury observed in intestinal models of I/R.
Xanthine Oxidase (XO)
The concept that XO-derived oxidants mediate the intes-
tinal injury associated with I/R was first proposed in 1981
[41]. Subsequently, several studies have supported this concept
and it is now considered that XO is a major source of oxidant
generation during I/R injury in the gastrointestinal tract.
In comparison with the other organs, the intestine can
generate high amounts of oxidants during I/R. The intestinal
mucosa has tremendous capacity to oxidize hypoxanthine via
the XO, which exists in normal healthy tissues predominantly
as a NAD+-reducing xanthine dehydrogenase (XD) [42].
Under ischemic conditions, XD rapidly converts to XO by
ischemia-mediated protease, and XO is capable of reducing
molecular oxygen to both O2˙− and H2O2 (Fig. 1) [39].
However, there are also adverse reports that the activity of
XO decreases during ischemia but increases subsequently
following reperfusion [43].
Intestinal ischemia reduces cellular ATP levels rapidly and
completely within 20 min while increasing the concentration
of AMP and hypoxanthine [23, 44, 45]. Menguy et al. also
reported that hemorrhagic shock resulted in a 75% reduction
in ATP, a 27% reduction in ADP, and a 350% increase in
AMP concentrations in the gastric mucosa within 15 min
[46]. Therefore, 30-min of ischemia is sufficient to produce
prolonged functional and structural changes in a rat intestine
[47]. ATP depletion results in loss of ATP-dependent ion
channel regulation, producing passive ion flux across the
cell membrane. Increased intracellular Ca2+ is harmful, one
of its important consequences being the activation of a
calcium-dependent protease, which cleaves of XD to form
Fig. 1.  Mechanism of xanthine oxidase-mediated free radical
injury. Modified from Granger et al [39].I/R in Gastrointestinal Tract
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XO. Fructose-1,6-biphosphate (F16BP), which is a high-
energy glycolytic intermediate [48], prevents the depletion
of intracellular ATP during ischemia. Thus, it prevents the
conversion of XD to XO [49] and inhibits free radical
production, [50] thereby protecting the intestine during the I/
R injury [51].
It can be estimated (assuming a tissue PaO2 of 20 mmHg)
that the XO activity measured in a cat intestine subjected
to I/R injury produced superoxide and hydrogen peroxide
fluxes of 1 and 40 nmol·min−1·g−1, respectively [39]. These
rates of oxidant production are cytotoxic to cells in culture
[52] and exceed the fluxes required to increase micro-
vascular permeability. Parks et al. have demonstrated that
intra-arterial infusion of XO (to achieve a plasma activity of
~2 mU/ml) in nonischemic intestines produced an increase
in microvascular permeability that is comparable to that
observed after I/R [53]. Furthermore, the cytotoxicity is
largely prevented by SOD and dimethyl sulfoxide (DMSO),
a hydroxyl radical scavenger, which supports the assumption
that these oxidants mediate the increased microvascular
permeability induced by arterial XO infusion.
Previous research supports the hypothesis that the intestine
appears to be the most sensitive to I/R injury among the
other internal organs [39, 54]. The intestine is composed of
labile enterocytes that are easily injured by episodes of
ischemia, and subsequent reperfusion results in further
damage to the intestinal mucosa. Enterocytes that are located
at the microvilli tips are more sensitive to the effect of
ischemia than those present in the crypts. This is because of
the their location at the end of the distribution of a central
arteriole and a relative lack of collateral blood flow, which
can result in a lower PaO2 in the distal enterocytes as
when compared with that in the crypts [55]. Intestinal XO
activity, which is one of the major sources of free radicals,
is found primarily in the mucosal layer with an increasing
gradient of activity from the villus base to the tip. This is
an additional reason for the increased sensitivity of the
villus tip to I/R injury as compared to that of the base [54].
Additionally, the differentiated enterocytes—located at the tip
of the microvilli—are inherently more sensitive to ischemia-
induced injury than their undifferentiated counterparts that
are located at the base [56].
Nitric Oxide (NO)
The role of nitric oxide (NO) in I/R injury is still contro-
versial. Inhibition of NO in certain models of I/R injury
causes tissue dysfunction, whereas it proves beneficial in
others.
NO is synthesized from L-arginine by a family of enzymes
known as NO synthase (NOS). The constitutive forms of
NOS (neural NOS: nNOS and endothelial NOS: eNOS) are
critical to normal physiology, and the inhibition of these
enzymes causes tissue injury [57]. However, the inducible
form of NOS (iNOS), which is only expressed in the
response to cytokines and growth factors, produces a large
amount of NO that contributes to the pathophysiology of I/R
injury. Therefore, while the use of selective inhibitors of iNOS,
namely, N(6)-(iminoethyl)-L-lysine (L-NIL) and ONO-1714
has been shown to be beneficial [58–60], the use of non-
selective inhibitors, namely, N(G)-nitro-L-arginine methyl ester
(L-NAME) has been shown to be deleterious in gastro-
intestinal I/R injury [61]. Additionally, iNOS knockout mice
are more resistant to intestinal I/R-induced bacterial trans-
location and mucosal injury, further supporting the role of
iNOS as an important mediator of I/R injury in the intestine
[62]. The nonselective NO inhibitors such as NG-monomethyl-
L-arginine (L-NMMA) and L-NAME aggravate the gastric
mucosal injury due to I/R, and this effect is blocked by L-
arginine [63].
Using an NO-sensitive electrode, Wada and his co-workers
measured the NO concentrations in the gastric mucosa and
concluded that NO has an important pathological role in
acute gastric mucosal injury induced by I/R [64]. They state
that the NO concentration in the gastric mucosa increases
during the ischemic period; subsequently, reperfusion causes
a rapid decrease to normal levels. NOS inhibitors prevent
both the increase in NO concentration during the ischemic
episode and the mucosal injury induced by I/R.
NO has many beneficial effects in the I/R injury
scavenging of oxygen free radicals, reduction of leukocyte
adhesion to the mesenteric endothelium, and maintenance of
normal vascular permeability [65–67]. During the early
phase of reperfusion, after ischemia, an increase in O2˙−
limits the accumulation of NO and prevents any of the
beneficial effects of NO; as a result, the leukocytes tend to
adhere to the endothelium [68]. Supplementation of NO using
NO donors such as FK-409, molsidomine, and nitroprusside
have been shown to attenuate gastrointestinal I/R injury [58,
69–71].
Endothelial Cells and Polymorphonuclear Neutro-
phils (PMNs)
Both endothelial cells and polymorphonuclear neutrophils
(PMNs) are another potential source of oxidants in the
gastrointestinal tract. NADPH oxidase is found in both these
cells, and reoxygenation promotes oxidant generation by
NADPH [32,  33]. Moreover, activated PMNs secrete a
variety of enzymes such as myeloperoxidase (MPO) and
elastase that can injure parenchymal cells and the micro-
vasculature [72].
Intravital microscopic studies of tissue exposed to I/R
injury reveal an acute inflammatory response that is charac-
terized by increased adhesion and emigration of PMNs
in postcapillary venules, microvascular permeability, andM. Sasaki and T. Joh
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mucosal injury [73]. Reduced PMNs and monoclonal anti-
bodies that interfere with the adhesion and emigration of the
PMNs across venules provide significant protection against
I/R injury [74, 75]. Determination of tissue-associated MPO
activity showed that the infiltration of PMNs in the mucosal
layer during the reperfusion period is significantly more than
that during ischemia [35]. The increased mucosal MPO
activity after reperfusion can be significantly attenuated by
the use of antioxidants. However, this attenuation of MPO
activity is reflective of the blockage of the recruitment of
PMNs into the mucosal layer rather than the inhibition of
MPO catalytic activity [39]. These observations suggest that
the adhesive interaction between PMNs and endothelial cells
plays a crucial role in I/R injury and this process mainly
depends on the oxidant stress.
Antioxidants: Protective Agents against Ischemia-
Reperfusion Injury
Under normal conditions, the oxygen molecule undergoes
a tetravalent reduction by the cytochrome system in the mito-
chondria to form water. However, one to two percent of the
oxygen molecules that escape this pathway undergoes uni-
valent reduction and generates oxygen-derived free radicals.
Under normal conditions, these radicals are neutralized by
endogenous antioxidant enzymes such as SOD and GSH,
thereby having no deleterious effect on the cells [76]. How-
ever, oxidative stress occurs when the production of oxidants
exceeds the capacity of the antioxidant defense systems of
the cell, or when the effectiveness of the antioxidant defense
system decreases. The human body has many natural anti-
oxidants; however, not all of them are capable of protection
against the attack of oxidants induced by the I/R condition.
Many animal studies have shown that antioxidant agents
are useful in protection against I/R-induced gastrointestinal
injury. XO inhibitors such as allopurinol, significantly reduce
the severity of intestinal mucosal lesions and gastric lesions
induced by I/R, [18, 19, 22, 77–80]. Enteral administration
of XO inhibitors such as pterin aldehyde or folic acid also
attenuates the I/R-induced increase in microvascular perme-
ability [81]. Although XO plays a crucial role in mucosal
damage during reperfusion, it is also provoke the injury
caused during the ischemic episodes [22].
Table lists antioxidant agents that have been reported to
be helpful in reducing I/R-induced tissue damage in the
intestine and stomach separately. The agents that have been
used are acetaminophen [82], allopurinol [18, 19, 22, 23,
77–80, 83–87], astragalus membranaceus [88], anti-thrombin
III [89], bilirubin [90, 91], captoprile [92], cimetidine [93], 5-
(2-amino-ethylamino)-1-phenyl-2-pentanone (compound IA)
[94], CV-6209—a platelet-activating factor antagonist [95],
cystathionine [96], cyclosporine [97, 98], desferrioxamine
[99–101], dimethyl sulfoxide (DMSO) [19, 83, 102–104],
edaravone [105], epidermal growth factor (EGF) [106, 107,
108], ellagic acid—one of the polyphenols [109], fullerenol
[110],  glutamine  [103,  111–113],  honey  [102,  114],  IT-
066—a novel histamine H2-receptor antagonist (H2RA)
[115], mannitol [116, 117], melatonin and its precursor L-
tryptophan [40,  118–127], methylprednisolone [116], N-
acetylecysteine (NAC) [117, 128–131], nitroglycerine [132,
133], pyrrolidine dithiocarbamate (PDTC) [134, 135], pyruvate
[136], rapamycin [97], rebamipide [100,  103,  137,  138],
rotenone [139], selenium [140, 141], SOD [18, 19, 22, 77–
79, 85, 142], sofalcone [143, 144], sucralfate [79, 145–148],
T-593—an H2RA [149, 150], 2,2,6,6-tetramethylpiperidine-
1-oxyl (TPL) [151], trimetazidine [152, 153], verapamil [87,
154, 155, 156], vitamin C [116, 117, 157–159], vitamin E
[116], and zinc N-(3-aminopropionyl)- L-histidine (Z-103)
[21].
Intravenous administration of N-acetylcysteine (NAC),
which is a free radical scavenger, has been proved to be
beneficial in protection against I/R injury of intestine [117,
128]; however, there are some controversial reports in this
regard [147,  160]. Some reports have demonstrated that
NAC treatment resulted in significant aggravation of the
gastric mucosal injury after I/R injury [147, 161]. Although
intraluminal perfusion of NAC increased the hexosamine
concentration, gastric mucus was significantly decreased.
This resulted in the exacerbation of the mucosal injury.
Some types of H2RA, which inhibit acid secretion by
parietal cells, are potent antioxidants and it has been
suggested that these exert a protective effect on I/R-induced
gastric mucosal injury. Although the luminal acid was
completely neutralized by NaOH instead of T-593 (an
H2RA), no reduction in the mucosal clearance was observed.
This indicated that the endogenous luminal acid does not
play an important role in gastric injury induced by localized
I/R stress [149]. Kitano demonstrated that compared to
luminal perfusion with an HCl solution alone, the luminal
perfusion with a solution containing HCl and H2RA, cime-
tidine (3 mmol/l) significantly reduced the total area of
erosions. Additionally, cimetidine (3 mmol/l) inhibited hydroxyl
radical-induced lipid peroxidation of human erythrocyte
membranes by 60% in vitro; this indicated that cimetidine
possesses a protective effect against acute gastric mucosal
injury induced by I/R not only due to the suppression of
gastric acid secretion but also due to its antioxidant
properties when it is present at high concentrations in the
intragastric environment [93]. Furthermore, Naito et al. [115]
showed that IT-066 (an H2RA) scavenged the superoxide
and hydroxyl radicals generated by the hypoxanthine-XO
system and the hydrogen peroxide-ferrous iron system,
respectively, by a spin trapping method using 5,5-dimethyl-
1-pyrroline-N-oxide.
Mucoprotective agents such as sofalcon, sucralfate, and
rebamipide have also been suggested to have antioxidantI/R in Gastrointestinal Tract
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Table. A list of antioxidant agents used agints ischemia-reperfusion injury in the intestine and stomach
Agent
Intestine Stomach
Author Outcome Reference Author Outcome Reference
Acetaminophen Nakamoto ↓ mucosal lesion 82
Allopurinol Parks ↓ histological damage, ↑ blood flow 38 Itoh ↓ mucosal lesion, ↓ XO 18
Schoenberg ↓ mucosal damage 23 Perry ↓ mucosal permeability 19
Haglund ↓ mucosal damage 77 Laudanno ↓ mucosal lesion 79
Bilbao ↓ histological damage, ↓ mortality 78 Alarcon de 
la Lastra
↓mucosal lesion, ↓mucosal neutrophils 84
Boros ↓ histological damage, ↑ blood flow 80 Zollei ↓ mucosal permeability, ↓ mucosal 
lesion, ↓ histological damage
85
Horne ↓ mucosal damage 83
Hakguder ↑ motility 86
Kulah ↓histological damage, ↓MDA, ↑GSH,
↓ LDH
87
Astragalus 
membranaceus
Hei ↓ histological damage, ↑ NO, 
↓ Endothelin-1, ↑ SOD, ↑ GSH
88
Anti-thrombin III Ozden ↓histological damage, ↓MPO, ↓MDA 89
Bilirubin Ceran ↓ histological damage, ↓ MDA 90
Hammerman ↓ histological damage, ↓ thiobarbituric 
acid-reducing substances
91
Captopril Buyukgebiz ↓ histological damage, ↓ MDA 92
Cimetidine Kitano ↓ mucosal lesion 93
Compound IA Poussios ↓ histological damage, ↓ MDA 94
CV-6209 Yoshikawa ↓ mucosal lesion, ↓ TBARS 95
Cystathionine Wada ↓ mucosal lesion, ↓ TBARS 96
Cyclosporine Puglisi ↓ histological damage 97, 98
Desferrioxamine Balogh ↓ MDA, ↓ TBARS, 
↓ 4-hydroxy-alkenals
101 Andrews ↓ histological damage 99
Kurokawa ↓ mucosal permeability 100
DMSO Horne ↓ mucosal damage 83 Perry ↓ mucosal permeability 19
Kojima ↓ apoptosis 103 Ali ↓mucosal lesion, ↓vascular permeability, 
↑ NP-SH
102
Dabareiner ↓microvascular permeability, ↓edema 104
Edaravone Tomatsuri ↓ mucosal damage, ↓ histological 
damage, ↓ TBARS, ↓ MPO, ↓ CINC-1
105
EGF Berlanga ↓ intraluminal bleeding, ↓ MPO, 
↓ MDA
106
Villa ↓ intestinal permeability, 
↓ histological damage
107
Martin ↓ mucosal damage 108
Ellagic acid Iino ↓ mucosal lesion, ↓ lipid peroxidation 109
Fullerenol Lai ↓histological damage, ↓MDA, ↑GSH 110
Glutamin Harward ↑ GSH, conjugated diene (a by-product of
lipid peroxidation) 
112 Stein ↓ mucosal lesion 111
Basoglu ↓ NO, ↑ GSH 113
Kojima ↓ apoptosis 103
Honey Koltuksuz ↓ mucosal damage, ↓ MDA 114 Ali ↓ mucosal lesion, ↓ vascular 
permeability, ↑ NP-SH 
102
IT-066 Naito ↓ mucosal lesion, ↓ O2, ↓ OH, 
↓ lipid peroxidation
115
Mannitol Gunel ↓histological damage, ↓MDA, ↑GSH 116
Byrka-Owczarek ↓ histological damage, ↑ blood flow 117
Melatonin 
(L-tryptophan )
Kazez ↓ histological damage, ↓ MDA 121 Konturek ↓ histological damage, ↑ blood flow 118, 119
Ustundag ↑ GSH-Px, ↑ SOD, ↑ selenium 122 Brzozowski ↓ mucosal lesion 120
Sileri ↓ bacterial translocation 126 Cabeza ↓ histological damage, ↓ XO, ↑ SOD, 
↑ GSH, ↑ PGE2
123, 124
Ates ↑catalase, ↑SOD, ↑GSH-Px, ↓MDA 40 Bulbuller ↓mucosal lesion, ↓histological damage 125
Ozacmak ↓ MDA, ↑ contraction, 
↓ histological damage, ↑ GSH
127
Methylprednisolone Gunel ↑ GSH 116
NAC Cuzzocrea ↓nitrosine, ↓PARS, ↓MPO, ↓MDA, 
↓ P-selectin, ↓ ICAM-1
128M. Sasaki and T. Joh
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Table. A list of antioxidant agents used agints ischemia-reperfusion injury in the intestine and stomach (continued)
Agent
Intestine Stomach
Author Outcome Reference Author Outcome Reference
Sun ↓ endothelial and epithelial 
permeability, ↓ MPO, ↓ IL-1beta 
129
Montero ↓ histological damage 130
Olanders ↓ endothelial permeability, 131
Byrka-Owczarek ↑ blood flow 117
Nitroglycerine Dun ↓histological damage, ↓MDA, ↓LDH 132
Khanna ↓ intestinal permeability, ↓ histological
damage,
133
PDTC Mallick ↑ blood flow, ↑ HO, ↓ LDH, 
↓ histological damage
134 El Eter ↓ vascular permeability, ↓ LDH, 
↓TNF-alpha, ↓TBARS, ↓NF-kappaB, 
↑ GSH
135
Pyruvate Cicalese ↓ histological damage, ↓ free radical 136
Rapamycin Puglisi ↓ histological damage 97
Rebamipide Kojima ↓ apoptosis 103 Kim ↓ MPO, ↓ MDA, ↑ SOD, ↑ NOS 137
Kurokawa ↓ mucosal permeability 100
Hiratsuka ↓ histological damage, ↓ COX2 138
Rotenone Ichikawa ↓ mucosal damage, ↓ TBARS, 
↓ CINC-1, ↓ TNF-alpha
139
Selenium Yoshida ↓ histological damage, 
↑ blood pressure
140
Ozturk ↓ histological damage, 
↓ bacterial translacation, ↓ MDA
141
SOD Parks ↓ histological damage, ↑ blood flow 22 Itoh ↓ mucosal lesion 18
Haglund ↓ mucosal damage 77 Perry ↓ mucosal permeability 19
Bilbao ↓ histological damage 78 Laudanno ↓ mucosal lesion 79
Riaz ↓ MDA, ↓ neutrophil rolling 
& adhesion
142 Zollei ↓ mucosal permeability, ↓ mucosal 
lesion, ↓ histological damage
85
Sofalcone Yoshikawa ↓ mucosal lesion, ↓ lipid peroxidation 143
Momo ↓ mucosal lesion, ↓ MDA 144
Sucralfate Sencan ↓ histological damage, ↓ enterocyte 
apoptosis
148 Laudanno ↓ mucosal lesion 79
al-Swayeh ↓ mucosal lesion, ↓ vascular 
permeability, ↓ superoxide, ↑ NP-SH 
145
Wada ↓ mucosal lesion, ↓ TBARS 146
Mojzis ↓ mucosal lesion, ↑ mucus 147
T-593 (H2RA) Seno ↓ mucosal permeability 149
Naito ↓ mucosal lesion 150
TPL Udassin ↓ intestinal permeabitily 151
Trimetazidine Tsimoyiannis ↓ peritoneal adhesion 152
Tetik ↓histological damage, ↓MDA, ↓MPO 153
Verapamil Mocan ↓ histological damage 155 Sato ↓ mucosal lesion, ↓ lipid peroxidation 154
Kulah ↓histological damage, ↓MDA, ↓GSH 87 al-Dohayan ↓ mucosal lesion 156
Vitamin C Nakamura ↓ histological damage, ↓ lipid 
peroxides, ↓ GSSH/GSH 
159 Ekman ↓ mucosal bleeding, ↑ vascular patency 157, 158
Gunel ↓histological damage, ↓MDA, ↓GSH 116
Byrka-Owczarek ↓ histological damage, ↑ blood flow 117
Vitamin E Gunel ↑ GSH 116
Z-103 Yoshikawa ↓ mucosal lesion 21
Compound IA: 5-(2-amino-ethylamino)-1-phenyl-2-pentanone
DMSO: dimethyl sulfoxide
EGF: epidermal growth factor
NAC: N-acetylecysteine
PDTC: pyrrolidinedithiocarbamate
SOD: superoxide dismutase
TPL: 2,2,6,6-tetramethylpiperidine-1-oxyl
Z-103: zinc N-(3-aminopropionyl)-L-histidineI/R in Gastrointestinal Tract
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properties; thus, they may prevent I/R-induced mucosal
injury. High concentrations of sucralfate (3–10 mg/ml) re-
duced the superoxide radicals generated by leukocytes or
xanthine-XO, and protected erythrocyte membrane ghosts
against lipid peroxidation induced by hydrogen peroxide
and Fe2+ in vitro [146]. The administration of sucralfate,
either before ischemia or before reperfusion, prevented the
gastrointestinal mucosal injury due to I/R stress [79, 145–
148]. Rebamipide also reduced gastrointestinal damage by
the pretreatment of ischemic changes [100, 103, 137, 138].
Only intraluminal administration of sofalcon before the onset
of ischemia has been proven to be effective in providing
gastric mucosal protection against I/R injury [143, 144].
Conclusion
Oxygen-derived free radicals play a major role in the
pathophysiological mechanism of ischemia-reperfusion injury
of the intestine. The sources of reactive oxygen species are
abundant, and the attenuation of oxidant stress minimizes
the extent of the ischemia-reperfusion injury. Therefore,
antioxidant agents play an important role in the treatment of
intestinal injury induced by ischemia-reperfusion.
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